BACKGROUND/AIMS: There are limited chemotherapy options for hepatocellular carcinoma (HCC). The heparin-degrading endosulfatase SULF1 functions as a liver tumor suppressor. We investigated the effects of the histone deacetylase inhibitor apicidin in combination with doxorubicin in SULF1-expressing HCC cells in vitro and in SULF1-expressing xenografts in nude mice. METHODS: We evaluated the effects of apicidin alone or combined with doxorubicin on apoptosis, caspase activity, and phosphorylation of Erk and Akt in SULF1-transfected Huh7 and Hep3B cells in vitro and in vivo. RESULTS: Apicidin induced HCC cell apoptosis and caspase activation in a dose- and time-dependent manner. Apicidin-induced caspase activation was significantly inhibited by the caspase inhibitor Z-Vad-fmk. Apicidin also decreased phosphorylation of both Erk and Akt. Expression of constitutively-active Mek1 and Akt significantly decreased apicidin-induced apoptosis. The combination of doxorubicin with apicidin significantly increased the anti-tumor effect in the SULF1-expressing Huh7 and Hep3B cells as compared to either apicidin or doxorubicin alone, both in vitro and in vivo. CONCLUSIONS: The combination of a histone deacetylase inhibitor with doxorubicin may be a novel and promising therapeutic modality for HCCs, particularly for SULF1-expressing HCCs.
BACKGROUND/AIMS: There are limited chemotherapy options for hepatocellular carcinoma (HCC). The heparin-degrading endosulfatase SULF1 functions as a liver tumor suppressor. We investigated the effects of the histone deacetylase inhibitor apicidin in combination with doxorubicin in SULF1-expressing HCC cells in vitro and in SULF1-expressing xenografts in nude mice. METHODS: We evaluated the effects of apicidin alone or combined with doxorubicin on apoptosis, caspase activity, and phosphorylation of Erk and Akt in SULF1-transfected Huh7 and Hep3B cells in vitro and in vivo. RESULTS:Apicidin induced HCC cell apoptosis and caspase activation in a dose- and time-dependent manner. Apicidin-induced caspase activation was significantly inhibited by the caspase inhibitor Z-Vad-fmk. Apicidin also decreased phosphorylation of both Erk and Akt. Expression of constitutively-active Mek1 and Akt significantly decreased apicidin-induced apoptosis. The combination of doxorubicin with apicidin significantly increased the anti-tumor effect in the SULF1-expressing Huh7 and Hep3B cells as compared to either apicidin or doxorubicin alone, both in vitro and in vivo. CONCLUSIONS: The combination of a histone deacetylase inhibitor with doxorubicin may be a novel and promising therapeutic modality for HCCs, particularly for SULF1-expressing HCCs.
Authors: Jinping Lai; Jeremy Chien; Julie Staub; Rajeswari Avula; Eddie L Greene; Tori A Matthews; David I Smith; Scott H Kaufmann; Lewis R Roberts; Viji Shridhar Journal: J Biol Chem Date: 2003-04-09 Impact factor: 5.157
Authors: J W Han; S H Ahn; S H Park; S Y Wang; G U Bae; D W Seo; H K Kwon; S Hong; H Y Lee; Y W Lee; H W Lee Journal: Cancer Res Date: 2000-11-01 Impact factor: 12.701
Authors: Josep M Llovet; Adrian M Di Bisceglie; Jordi Bruix; Barnett S Kramer; Riccardo Lencioni; Andrew X Zhu; Morris Sherman; Myron Schwartz; Michael Lotze; Jayant Talwalkar; Gregory J Gores Journal: J Natl Cancer Inst Date: 2008-05-13 Impact factor: 13.506
Authors: Jin-Ping Lai; Dalbir S Sandhu; Chunrong Yu; Catherine D Moser; Chunling Hu; Abdirashid M Shire; Ileana Aderca; Linda M Murphy; Alex A Adjei; Schuyler Sanderson; Lewis R Roberts Journal: Liver Int Date: 2010-09-08 Impact factor: 5.828
Authors: Renumathy Dhanasekaran; Ikuo Nakamura; Chunling Hu; Gang Chen; Abdul M Oseini; Elif Sezin Seven; Alexander G Miamen; Catherine D Moser; Wei Zhou; Toin H van Kuppevelt; Jan M van Deursen; Taofic Mounajjed; Martin E Fernandez-Zapico; Lewis R Roberts Journal: Hepatology Date: 2015-02-13 Impact factor: 17.425
Authors: Abdirashid Shire; Gwen Lomberk; Jin-Ping Lai; Hongzhi Zou; Norihiko Tsuchiya; Ileana Aderca; Catherine D Moser; Kadra H Gulaid; Abdul Oseini; Chunling Hu; Omar Warsame; Robert B Jenkins; Lewis R Roberts Journal: Med Epigenet Date: 2015 Jan-Apr